Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 7, 2012, Pages 618-624

  Dankner, R ^a,b,c   Chetrit, A ^a   Shanik, M H ^d,e   Raz, I ^f   Roth, J ^c,g  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d Endocrine Associates of Long Island   (United States)

^e STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Basal hyperinsulinemia; Dysglycemia; Follow up; Predictors

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DIABETES MELLITUS; DISEASE COURSE; DYSGLYCEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; ISRAEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERINSULINISM; INSULIN; ISRAEL; MALE; MIDDLE AGED; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS; SEX CHARACTERISTICS;

EID: 84867071445     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2322     Document Type: Article

References (51)

1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003; 289: 76-79.
2. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7years before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
3. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24(2): 137-144.
4. Sandbaek A, Griffin SJ, Rutten G, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51(7): 1127-1134.
5. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
6. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group: prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group: acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2097.
9. Katula JA, Vitolins MZ, Rosenberger EL, et al. One-year results of a community-based translation of the Diabetes Prevention Program: Healthy-Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care 2011; 34(7): 1451-1457.
10. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest 1975; 55: 454-461.
11. Reaven GM, Bernstein R, Davis B, Olefsky JM. Non-ketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976; 60: 80-88.
12. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001; 86: 3574-3578.
13. Lorenzo C, Hazuda HP, Haffner SM. Insulin Resistance and Excess Risk of Diabetes in Mexican-Americans: The San Antonio Heart Study. J Clin Endocrinol Metab 2012; 97(3): 793-799.
14. Yalow RS, Glick SM, Roth J, Berson SA. Plasma insulin and growth hormone levels in obesity and diabetes. Ann N Y Acad Sci 1965; 131(1): 357-373.
15. Sicree RA, Zimmet PZ, King HOM, Conventry JS. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 years. Diabetes 1987; 36: 179-186.
16. Haffner SM, Stern MP, Mitchell BD, Hazua HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity and body-fat distribution. Diabetes 1990; 39: 283-288.
17. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of the diabetic parents. Ann Intern Med 1990; 113: 909-915.
18. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992.
19. Marban SL, Roth J. Transgenic hyperinsulinemia: a mouse model of insulin resistance and glucose intolerance without obesity. In Lessons from Animal Diabetes VI (6th edn), Shafrir E (ed). Birkhauser: Boston, 1996; 201-224.
20. Roth J, Qiang X, Marban SL, Redel H, Lowell BC. The obesity pandemic: where have we been and where are we going? Obes Res 2004; 12: 88S-101S.
21. Shanik MH, Xu Y, Škrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31(Suppl. 2): S262-S268.
22. Hannon TS, Bacha F, Lin Y, Arslanian SA. Hyperinsulinemia in African-American adolescents compared with their American White peers despite similar insulin sensitivity: a reflection of upregulated β-cell function? Diabetes Care 2008; 31: 1445-1447.
23. Svec F, Nastasi K, Hilton C, Bao W, Srinivasan SR, Berenson GS. Black-white contrasts in insulin levels during pubertal development: the Bogalusa Heart Study. Diabetes 1992; 41: 313-317.
24. Pettit DJ, Moll PP, Knowler WC, et al. Insulinemia in children at low and high risk for NIDDM. Diabetes Care 1993; 16: 608-615.
25. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. Evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 2000; 49: 2094-2101.
26. Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in African- American children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes 2002; 51: 3014-3019.
27. Bergman M. Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes Metab Res Rev 2010; 26(1): 3-6.
28. Dankner R, Danoff A, Roth J. Can "personalized diagnostics" promote earlier intervention for dysglycemia? Hypothesis ready for testing. Diabetes Metab Res Rev 2010; 26(1): 7-9.
29. Modan M, Lubin F, Lusky A, Chetrit A, Fuchs Z, Halkin H. Interrelationships of obesity, habitual diet, physical activity and glucose intolerance in the four main Israeli Jewish ethnic groups: the Israel GOH study. In Recent Advances in Obesity, Research V, Berry EM, Blondheim SH, Eliahou EH, Shafrir E (eds). John Libbey: London, 1982; 46-59.
30. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.
31. Modan M, Halkin H, Fuchs Z. Hyperinsulinemia - a link between glucose intolerance, obesity, hypertension, dyslipoproteinemia, elevated serum uric acid and internal cation imbalance. Diabetes Metabol 1987; 13: 375-380.
32. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
33. Cerasi E, Ependic S, Luft R. Dose-response relation between plasma-insulin and blood-glucose levels during oral glucose loads in prediabetic and diabetic subjects. Lancet 1973; 1(7807): 794-797.
34. Passey RB, Gillum RL, Fuller JB, Urry FM, Giles ML. Evaluation and comparison of 10 glucose methods and the reference method recommended in the proposed product class standard (1974). Clin Chem 1997; 23: 131-139.
35. Manual of Laboratory Operations. Lipid research clinics program. Volume 1. Lipid and Lipoprotein Analysis. National Heart and Lung Institute, National Institutes of Health. Bethesda, MD. DHEW Publication No. (NIH) 1979; 75-628.
36. Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002; 19(9): 724-729.
37. Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care 2009 Aug; 32(8): 1464-1466.
38. Tabak AG, Jokela M, Adbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221.
39. Li C, Ford ES, MCGuire LC, Mokdad AH, Little RR, Reaven GM. Trends in hyperinsulinemia among nondiabetic adults in the U.S. Diabetes Care 2006; 29: 2396-2402.
40. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. NEJM 2002; 346(11): 802-810.
41. Morrison JA, Glueck CJ, Umar M, Daniels S, Dolan LM, Wang P. Hyperinsulinemia and metabolic syndrome at mean age of 10years in black and white schoolgirls and development of impaired fasting glucose and type 2 diabetes mellitus by mean age of 24years. Metabolism 2010 Jan. 21 [epub ahead of print].
42. Kim DJ, Kim KW, Cho NH, Noh JH, Lee MS, Lee MK. The cut-off value of fasting plasma glucose to differentiate frequencies of cardiovascular risk factors in a Korean population. Diabetes Care 2003; 26: 3354-3356.
43. Thomas GN, Chook P, Qiao M, et al. Deleterious impact of "high normal" glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004; 24: 739-743.
44. Tirosh A, Shai I, Tekes-Manova D, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454-1462.
45. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698-702.
46. Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf) 1990; 32: 689-693.
47. Saad MF, Kahn SE, Nelson RG. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1990; 70: 1247-1253.
48. Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 1993; 76: 44-48.
49. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 341-353.
50. Porte D, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005; 54(5): 1264-1276.
51. Plum L, Belgardt BF, Brüning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest 2006; 116(7): 1761-1766.